A biomaterial includes a neutral acyl lipid and an amphipathic block copolymer which contains a hydrophilic segment and a hydrophobic segment and in which a difference in ClogP value between the hydrophilic segment and the hydrophobic segment is more than 1.00, and in the biomaterial, a content of the amphipathic block copolymer is 1.0% to 20% by mass with respect to a total mass of a solid content of the biomaterial.

Materials and methods for formulating skin care compositions suitable for use on babies and toddlers are provided herein. For example, this document provides materials and methods for formulating diaper cream compositions that contain natural ingredients, are not irritating to babies' skin, and can be used to treat or prevent symptoms of diaper rash.

Materials and methods for formulating skin care compositions suitable for use on babies and toddlers are provided herein. For example, this document provides materials and methods for formulating diaper cream compositions that contain natural ingredients, are not irritating to babies' skin, and can be used to treat or prevent symptoms of diaper rash.

##STR00001##

Use of a compound having the formula (1) (2) (3) or (4) or combinations thereof, for increasing blood ketone levels, and/or treating a disease treatable by increasing blood ketone levels, preferably wherein the disease is selected from the list consisting of: a brain energy deficiency condition, a neurological condition, migraine, memory disorder, age-related memory disorder, brain injury, stroke, amyloid lateral sclerosis, multiple sclerosis, cognitive impairment, cognitive impairment post-intensive care, age-induced cognition impairment, Alzheimer's disease, Parkinson's disease, Huntingdon's disease, inherited metabolic disorders (such as glucose transporter type 1 deficiency syndrome and pyruvate dehydrogenase complex deficiency), depression, schizophrenia, epilepsy, narcolepsy, diabetes, obesity, non-alcoholic fatty liver disease and polycystic ovary syndrome, wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5 and R.sup.6 are independently a long chain fatty acid having between 16 and 20 carbons.

##STR00001##

Use of a compound having the formula (1) (2) (3) or (4) or combinations thereof, for increasing blood ketone levels, and/or treating a disease treatable by increasing blood ketone levels, preferably wherein the disease is selected from the list consisting of: a brain energy deficiency condition, a neurological condition, migraine, memory disorder, age-related memory disorder, brain injury, stroke, amyloid lateral sclerosis, multiple sclerosis, cognitive impairment, cognitive impairment post-intensive care, age-induced cognition impairment, Alzheimer's disease, Parkinson's disease, Huntingdon's disease, inherited metabolic disorders (such as glucose transporter type 1 deficiency syndrome and pyruvate dehydrogenase complex deficiency), depression, schizophrenia, epilepsy, narcolepsy, diabetes, obesity, non-alcoholic fatty liver disease and polycystic ovary syndrome, wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5 and R.sup.6 are independently a long chain fatty acid having between 16 and 20 carbons.

The disclosure provides methods for treating, controlling or mitigating leukopenia (e.g. neutropenia) and/or thrombocytopenia, for example in the context of cancer chemotherapy, comprising administration of a monoacetyl-diacyl-glycerol compound, as well as compositions useful therefor.

The disclosure provides methods for treating, controlling or mitigating leukopenia (e.g. neutropenia) and/or thrombocytopenia, for example in the context of cancer chemotherapy, comprising administration of a monoacetyl-diacyl-glycerol compound, as well as compositions useful therefor.

The disclosure provides methods for treating, controlling or mitigating leukopenia (e.g. neutropenia) and/or thrombocytopenia, for example in the context of cancer chemotherapy, comprising administration of a monoacetyl-diacyl-glycerol compound, as well as compositions useful therefor.

The present invention relates to bovine milk fat comprising, based on total fatty acid content, 8.9-29.0 wt % linoleic acid (C18:2 cis, 9,12), 0.9-2.4 wt % alpha-linolenic acid (C18:3 cis 9,12,15), and 3-5 wt % butyric acid (C4:0). The present invention further relates to a bovine milk comprising said milk fat and to a method for producing said milk by feeding a lactating bovine mammal with a rumen-protected linoleic acid source and a rumen-protected alpha-linolenic acid source, followed by milking the lactating bovine animal.

The present invention relates to bovine milk fat comprising, based on total fatty acid content, 8.9-29.0 wt % linoleic acid (C18:2 cis, 9,12), 0.9-2.4 wt % alpha-linolenic acid (C18:3 cis 9,12,15), and 3-5 wt % butyric acid (C4:0). The present invention further relates to a bovine milk comprising said milk fat and to a method for producing said milk by feeding a lactating bovine mammal with a rumen-protected linoleic acid source and a rumen-protected alpha-linolenic acid source, followed by milking the lactating bovine animal.